Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial

被引：0
|
作者：
Cork, Michael J. [1 ]
Beck, Lisa A. [2 ]
Deleuran, Mette [3 ]
Hong, H. Chih-ho [4 ,5 ]
Adam, David N. [5 ,6 ,7 ]
Hussain, Iftikhar [8 ]
Zhang, Haixin [9 ]
Shabbir, Arsalan [9 ]
Rodriguez Marco, Ainara [10 ]
Levit, Noah A. [9 ]
机构：
[1] Univ Sheffield, Sheffield Dermatol Res, Sheffield, S Yorkshire, England
[2] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Univ British Columbia, Surrey, BC, Canada
[5] Prob Med Res, Waterloo, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] CCA Med Res, Ajax, ON, Canada
[8] Vital Prospects Clin Res Inst, Tulsa, OK USA
[9] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[10] Sanofi Genzyme, Madrid, Spain
来源：
CLINICAL AND EXPERIMENTAL ALLERGY | 2022年 / 52卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P034
引用
收藏
页码：1014 / 1014
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy of dupilumab in adults with moderate-tosevere atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years
    Thyssen, Jacob P.
    Blauvelt, Andrew
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB180 - AB180
  • [32] JAAD Game Changers: Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Wohltmann, Wendi E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 613 - 613
  • [33] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [34] Laboratory safety of long-term dupilumab treatment in a 5-year open-label extension study of adults with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Bissonnette, R.
    Deleuran, M.
    Nakahara, T.
    Galus, R.
    Khokhar, F. A.
    Coleman, A.
    Gherardi, G.
    Chen, Z.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364
  • [35] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E96
  • [36] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman, Emma
    Hussain, Iftikhar
    Chen, Zhen
    Mina-Osorio, Paola
    Rossi, Ana Beatris
    Bansal, Ashish
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB141 - AB141
  • [37] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Worrell, R.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 29 - 31
  • [38] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    [J]. DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
  • [39] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Kim A. Papp
    Saskia de Vente
    Jiewei Zeng
    Mary Flack
    Byron Padilla
    Stephen K. Tyring
    [J]. Dermatology and Therapy, 2021, 11 : 487 - 497
  • [40] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
    Blauvelt, Andrew
    Langley, Richard G.
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew E.
    Peris, Ketty
    Fangel, Stine
    Gjerum, Le
    Corriveau, Joshua
    Saeki, Hidehisa
    Warren, Richard B.
    Simpson, Eric
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
12345